C2CD3

Across TCGA pan-cancer cohorts, C2CD3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C2CD3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C2CD3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C2CD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, UCEC, and LSCC are the cancer types where C2CD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.489	0.762	.001	17	view →
UCEC	OS	Median	III,IV	0.464	1.000	.023	8	view →
LSCC	OS	Tertile	III,IV	0.864	0.438	.033	4	view →
GBM	OS	Median	All	0.766	0.921	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C2CD3–LUAD (DFS)

Open the LUAD breakdown →